Indications and uses
helps prevent and reduce: plaque gingivitis
helps prevent and reduce: plaque gingivitis
rinse full strength for 30 seconds with 20 ml (2/3 fluid ounce or 4 teaspoonfuls) morning and night do not swallow
store at room temperature cold weather may cloud this product. Its antiseptic properties are not affected.
Drug Facts
| Active ingredients | Purposes |
|---|---|
| Eucalyptol 0.092% } Menthol 0.042% } Methyl salicylate 0.060% } Thymol 0.064% } | Antiplaque/antigingivitis |
helps prevent and reduce:
Do not use in children under 12 years of age
Keep out of reach of children. If more than used for rinsing is accidentally swallowed, get medical help or contact a Poison Control Center right away.
water, alcohol (26.9%), benzoic acid, poloxamer 407, sodium benzoate, caramel
call 1-888-222-0182, weekdays
Dist: Johnson & Johnson Healthcare Products
Division of McNEIL-PPC, Inc.
Skillman, NJ 08558-9418 USA
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Eucalyptol | ACTIVE INGREDIENT | RV6J6604TK | 1 | |
| Menthol | ACTIVE INGREDIENT | L7T10EIP3A | 1 | |
| Methyl Salicylate | ACTIVE INGREDIENT | LAV5U5022Y | 1 | |
| Thymol | ACTIVE INGREDIENT | 3J50XA376E | 1 | |
| Eucalyptol | ACTIVE MOIETY | RV6J6604TK | 1 | |
| Menthol | ACTIVE MOIETY | L7T10EIP3A | 1 | |
| Methyl Salicylate | ACTIVE MOIETY | LAV5U5022Y | 1 | |
| Thymol | ACTIVE MOIETY | 3J50XA376E | 1 | |
| Alcohol | INACTIVE INGREDIENT | 3K9958V90M | 1 | |
| Benzoic Acid | INACTIVE INGREDIENT | 8SKN0B0MIM | 1 | |
| Caramel | INACTIVE INGREDIENT | T9D99G2B1R | 1 | |
| Poloxamer 407 | INACTIVE INGREDIENT | TUF2IVW3M2 | 1 | |
| Sodium Benzoate | INACTIVE INGREDIENT | OJ245FE5EU | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 42002-401 | 42002-401-73, 42002-401-72, 42002-401-71, 42002-401-70, 42002-401-63, 42002-401-94, 42002-401-95 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Eucalyptol | RV6J6604TK | ACTIB |
| Menthol, Unspecified Form | L7T10EIP3A | ACTIB |
| Methyl Salicylate | LAV5U5022Y | ACTIB |
| Thymol | 3J50XA376E | ACTIB |
| Water | 059QF0KO0R | IACT |
| Alcohol | 3K9958V90M | IACT |
| Benzoic Acid | 8SKN0B0MIM | IACT |
| Poloxamer 407 | TUF2IVW3M2 | IACT |
| Sodium Benzoate | OJ245FE5EU | IACT |
| Caramel | T9D99G2B1R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Caramel | CARAMEL | T9D99G2B1R | SOLUTION / ORAL | 11 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / TOPICAL | 2445 mg | ||
| Caramel | CARAMEL | T9D99G2B1R | LOTION / TOPICAL | NA | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | SYRUP / ORAL | 80 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | GEL / RECTAL | 406 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | GEL / TRANSDERMAL | 7360 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / INTRAVESICAL | 7892 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | INJECTION / INTRAVASCULAR | 100 %v/v | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | PASTE / DENTAL | 0.08 %w/w | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SOLUTION / IRRIGATION | 0.02 %w/v | ||
| Alcohol | ALCOHOL | 3K9958V90M | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SWAB / TOPICAL | 2250 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | POWDER, FOR SOLUTION / ORAL | 98 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SUSPENSION / ORAL | 15 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | PASTE, DENTIFRICE / DENTAL | 0.5 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | SOLUTION / TOPICAL | 0.1 %w/v | ||
| Alcohol | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / SUBCUTANEOUS | 6.1 %v/v | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | GEL / TOPICAL | 28 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | CREAM / VAGINAL | 10 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | INJECTION, EMULSION / INTRAVENOUS | 0.1 %w/v | ||
| Caramel | CARAMEL | T9D99G2B1R | CREAM / TOPICAL | 0.26 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | LIQUID / INTRAMUSCULAR | 400 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | GEL, METERED / TRANSDERMAL | 3675 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | POWDER, FOR SOLUTION / TOPICAL | 40 %w/w | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | SOLUTION / OPHTHALMIC | 0.2 %w/v | ||
| Alcohol | ALCOHOL | 3K9958V90M | TABLET, DELAYED RELEASE / ORAL | NA | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | GRANULE, FOR SUSPENSION / ORAL | 120 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SHAMPOO / TOPICAL | 714 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | SUSPENSION, EXTENDED RELEASE / ORAL | 24 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | AEROSOL / NASAL | 20 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | INJECTION / INTRAVENOUS | 92 %w/v | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | CREAM / TOPICAL | 0.2 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / DENTAL | 12.8 %w/w | ||
| Alcohol | ALCOHOL | 3K9958V90M | SOLUTION / ORAL | 6624 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SYRUP / ORAL | 20 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | GRANULE, EFFERVESCENT / ORAL | 60 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | GRANULE / ORAL | NA | ||
| Alcohol | ALCOHOL | 3K9958V90M | LIQUID / RESPIRATORY (INHALATION) | 5 %w/w | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | INJECTION, SOLUTION / INTRAMUSCULAR | 4.8 %w/v | ||
| Caramel | CARAMEL | T9D99G2B1R | GRANULE, FOR SUSPENSION / ORAL | 2.5 mg/5ml | ||
| Alcohol | ALCOHOL | 3K9958V90M | JELLY / VAGINAL | NA | ||
| Alcohol | ALCOHOL | 3K9958V90M | SYRUP / ORAL | 21000 mg | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | POWDER, FOR SUSPENSION / ORAL | 160 mg | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | CAPSULE, DELAYED RELEASE / ORAL | 5 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | LIQUID / ORAL | 2 mg/1ml | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | CREAM / TOPICAL | 13 mg | ||
| Poloxamer 407 | POLOXAMER 407 | TUF2IVW3M2 | SOLUTION / ORAL | 50 mg/5ml | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | SOLUTION / ORAL | 660 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | MOUTHWASH / BUCCAL | NA | ||
| Alcohol | ALCOHOL | 3K9958V90M | LIQUID / ORAL | 3563 mg | ||
| Alcohol | ALCOHOL | 3K9958V90M | CONCENTRATE / BUCCAL | 679 mg/1ml | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SOLUTION / TOPICAL | 0.1 %w/w | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | TABLET, DELAYED RELEASE / ORAL | 0.34 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | INJECTION / INTRAMUSCULAR | 5 %w/v | ||
| Sodium Benzoate | SODIUM BENZOATE | OJ245FE5EU | SPONGE / TOPICAL | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5514d206-f86c-48c0-998f-0251118c10e1 | 56f1e582-807c-43bb-b680-98e13852199f | 2020-09-09 | Warnings | 5514d206-f86c-48c0-998f-0251118c10e1 56f1e582-807c-43bb-b680-98e13852199f |
Adverse event summaries are temporarily unavailable. Other product information remains available.